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Roger M. Nitsch and Christoph Hock have founded 
Neurodegenerative Diseases in 2004, and, thanks to their 
own and the editorial board’s scientific expertise and un-
tiring efforts, within a short time this journal has become 
a most lively and thriving meeting place in a fascinating 
and extremely promising subdiscipline of neuroscience. 
It is here where up-to-date research on neurobiological 
mechanisms is disseminated, offering an ever better un-
derstanding of Alzheimer (AD) and Parkinson disease, 
monogenetic autosomal disorders such as Huntington 
disease (HD), and many more disorders of the nervous 
system.
It is a great privilege to succeed as editor-in-chief the 
founding editors of this journal beginning in 2018, and I 
very much look forward to continue, supported by its ex-
perienced editorial board, its tradition of rapid publica-
tion of outstanding novel scientific studies. 
Newly invited associate editors represent innovative 
methodological approaches in a dynamically expanding 
field, and it is based on their frontline expertise that Neu-
rodegenerative Diseases will be able to evaluate, accept, 
and introduce to the scientific community the most con-
vincing research methodologies and findings in brain 
studies.
Considering the development of disease-modifying 
therapeutic interventions for neurodegenerative brain 
disorders as a major goal of research, novel insights into 
brain changes prior to the manifestation of clinical syn-
dromes are most promising. A better understanding of 
pathological sequences and neurobiological mechanisms 
implicated in these very early “preclinical” disease stages 
is regarded to lay open cellular vulnerability factors as a 
major factor of the etiology and pathogenesis of neurode-
generative disorders including AD [1, 2], Parkinson [3], 
amyotrophic lateral sclerosis [4–6], and HD [7]. The 
identification of the relevant pathology in individuals at 
a point in time early enough for administering disease-
modifying therapy before irreversible neurodegenerative 
brain damage has commenced may represent a particular 
challenge for clinical research trials [8]. Recently pub-
lished, encouraging first results of antibody-based thera-
py in AD [9] underline the potential of early and pathol-
ogy-specific intervention, but also the need for improving 
diagnostic capabilities for detecting clinically inconspicu-
ous individuals at increased risk.
A few hints at the research foci and most recent find-
ings of colleagues who have followed our invitation to 
form the new team of Associate Editors of Neurodegen-
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erative Diseases may suffice here to evidence our empha-
sis on bringing together a broadly based expertise that is 
able both to stimulate new conceptual and methodologi-
cal approaches in the field and to attract pertinent find-
ings to be published in our journal.
Thematically, Neurodegenerative Diseases will certain-
ly continue to focus on the investigation of molecular 
mechanisms and basic biology. Recent work by Magda-
lini Polymenidou and her group at the University of Zu-
rich points to a central role of functional and dynamic 
polymerization of the protein TDP-43 as a precondition 
of its pathological aggregation in amyotrophic lateral 
sclerosis, and possibly also its self-perpetuating, prion-
like properties [10–12]. Wenzhen Duan is an expert in 
single gene mutations and autosomal dominant disorders 
at Johns Hopkins University [13–15]. Her own and her 
team’s research has resulted in the hypothesis that expan-
sion mutations as observable in HD may also have an eti-
ological role in more frequent psychiatric diseases [16, 
17], allowing for novel therapeutic approaches [18]. Gene 
therapy aimed at single pathological targets, as performed 
by Janine Reichenbach and her team at the University of 
Zurich [19–21], might thus attain therapeutic relevance 
beyond the initially targeted monogenetic disorder. Ro-
dent models play a fundamental role to test novel mecha-
nistic hypotheses as well as the resulting therapeutic in-
terventions. Jan Klohs, from the Swiss Federal Institutes 
of Technology (ETH) and the University of Zurich, has 
demonstrated the potential of preclinical imaging for the 
determination of neurodegenerative and vascular pathol-
ogy in various experimental settings [22–24].
A novel thematic focus of the Journal Neurodegenera-
tive Diseases shall be the translation of laboratory findings 
to clinical research. To this effect, the state-of-the-art im-
plementation of clinical research methodology and the 
establishment of informative biomarkers will play a deci-
sive role. Adam Brickman, from Columbia University, is 
an expert in this emerging research field, and recent work 
of him and his team has substantially contributed to bet-
ter understand the role of white matter pathology in AD 
[25, 26] and the interplay between vascular disease and 
AD pathology [27, 28]. Considering the complexity of the 
clinical phenotype observable during the progression of 
neurodegenerative syndromes, interactive effects be-
tween genetic determination and environmental factors 
might be accountable [29, 30]. Here, biological pheno-
types of increased risk may provide information on ge-
netic variation associated with sporadic AD and other 
neurodegenerative disorders [31–33]. Stephan Ripke is 
an expert in statistical genetics at Harvard Medical School 
and Charité Universitaetsmedizin Berlin. His work and 
methodological input were vital for the recent progress in 
the characterization of genetic signatures of frequent psy-
chiatric disorders including polygenetic effects and copy 
number variation [34–38], which might also be informa-
tive for a better understanding of the inherited liability for 
neurodegenerative disease. Neuroimaging has proven 
valid both for the early diagnosis of neurodegenerative 
disorders [1, 2], the noninvasive assessment of molecular 
and metabolic properties [39, 40], and also as a measure 
of therapeutic target engagement [9]. Recently, infer-
ences on progression of β-amyloid-associated cognitive 
decline have been made using magnetic resonance imag-
ing of local susceptibility [41]. Jun Hua is an expert in 
clinical neuroimaging at Johns Hopkins University. He 
will provide particular expertise in the application of nov-
el techniques allowing for the quantification of vascular 
and functional brain changes [42, 43], which are frequent 
findings in early and preclinical AD and HD [1, 7]. More-
over, considering the impact of subcortical and hippo-
campal damage for the emergence of the clinical picture 
of various neurodegenerative disorders, a particular the-
matic focus will be set on neuroimaging approaches of 
this brain region, as established by Christine Tardif and 
her team at McGill University [44–46]. The standardized 
assessment of relevant brain changes and the investiga-
tion of their potential value for inferring on the progres-
sion of neurodegenerative disorder require novel and 
flexible data analysis strategies. Ender Konukoglu is an 
expert in mathematical and computational algorithms at 
ETH, and his expertise in biomedical image analysis 
has substantially contributed to recent advances in the 
prediction of individual disease courses and pathology 
[47–50].
We are well aware of the challenges ahead of us. Suc-
cessful scientific work requires not only individual exper-
tise, but also solid networks for a continuous exchange 
among the best researchers in the field and a platform 
where, in addition to conferences and personal commu-
nication, progress is documented for a wider interested 
and participating readership. Neurodegenerative Diseases 
will continue to be this sought-after platform, and all of 
us involved look forward to what promise to be fascinat-
ing developments aimed at freeing mankind of some of 
its most dreaded disease burdens.
Paul G. Unschuld
 Editor-in-Chief Neurodegenerative Diseases,  
January 1, 2018
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